Express News | Eli Lilly and Co's treatment drug has been granted orphan drug status by the FDA.
Express News | Mangoceuticals Inc: Responds to Claims Made by Eli Lilly
Lilly Sues Companies Selling Compounded Zepbound, Mounjaro
Buy ahead of time in 2016? Benefiting from the 'Trump trade,' assets are outpacing the market, but this time 'it's somewhat different.'
Republican presidential candidate Trump's polls are reversing, and the 'winning odds' are gradually increasing. A Merrill Lynch strategist pointed out that investors seem to be rushing to allocate to symbols that performed well after Trump's victory in 2016. What inspiration does this have for investment?
Sector Update: Health Care Stocks Slide Monday Afternoon
Sector Update: Health Care
Goldman's High Growth Investment Ratio Stocks: EA, AMZN, FANG, Etc
Goldman Sachs, Morgan Stanley Bullish on BioAge, Cite Lilly Relationship
Novo Nordisk Semaglutide Cut Cardio Risks by 14% in Diabetics: Study
Goldman Sachs Adjusts Price Target on Eli Lilly and Co. to $890 From $856
Market Chatter: Eli Lilly Files Suits Against Companies Selling Weight-Loss Drug
Eli Lilly and Co (LLY.US) sues three American entities for "counterfeiting" their own brand of weight loss drugs.
eli lilly and co announced on Monday that it has sued three medical spas and online retailers, claiming that their products contain terlipressin.
Barclays Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,025
Express News | Lilly Sues Mangorx, Pivotal Peptides, Genesis Lifestyle Medicine of Nevada for Selling Versions of Tirzepatide - Court Filings
Eli Lilly (LLY): Revenue Boost From Zepbound and Mounjaro Amid Strong Market Projections
'FDA Won't Take Action Against GLP-1 Compounders As It Rethinks Tirzepatide Shortage' - Endpoints News
Behind the Scenes of Eli Lilly's Latest Options Trends
OAC and Eli Lilly and Company Partner to Launch Bias-Free Obesity Image Gallery at HLTH 2024
"Trump Trade" is restarting, what are the differences?
The new change of the "Trump trade" is that US technology stocks are more resilient, energy stocks are weaker, US bond yields are falling instead of rising, and gold is performing stronger. Ping An Securities believes that the current situation is still in a stalemate, and it is uncertain how far the "Trump trade" can go.
Leerink Partners Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $990